Analyst Ratings Network logo

NASDAQ:TPTX - Turning Point Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $137.43
  • Forecasted Upside: 4.43 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$131.60 As of 01/15/2021 01:00 AM ET
▼ -5.39 (-3.93%)
1 month | 3 months | 12 months
Get New Turning Point Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TPTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TPTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$137.43
▲ +4.43% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Turning Point Therapeutics in the last 3 months. The average price target is $137.43, with a high forecast of $160.00 and a low forecast of $122.00. The average price target represents a 4.43% upside from the last price of $131.60.
Buy
The current consensus among 7 investment analysts is to buy stock in Turning Point Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/19/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/17/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/16/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2021JMP SecuritiesBoost Price Target$125.00 ➝ $160.00Medium
i
1/12/2021OppenheimerBoost Price TargetOutperform$130.00 ➝ $150.00Medium
i
12/14/2020SVB LeerinkBoost Price TargetOutperform$116.00 ➝ $127.00High
i
12/8/2020Roth CapitalBoost Price Target$133.00 ➝ $140.00Medium
i
12/8/2020JMP SecuritiesInitiated CoverageOutperform$125.00High
i
11/13/2020OppenheimerBoost Price TargetOutperform$120.00 ➝ $130.00Medium
i
Rating by Matthew Biegler at Oppenheimer Holdings Inc.
10/30/2020Roth CapitalBoost Price TargetBuy$77.00 ➝ $133.00Medium
i
10/27/2020Canaccord GenuityBoost Price TargetBuy$85.00 ➝ $122.00High
i
10/26/2020Wells Fargo & CompanyBoost Price TargetOverweight$88.00 ➝ $133.00High
i
10/26/2020HC WainwrightBoost Price TargetBuy$100.00 ➝ $130.00High
i
Rating by Robert Burns at HC Wainwright
10/26/2020SVB LeerinkBoost Price TargetOutperform$77.00 ➝ $116.00High
i
10/25/2020OppenheimerBoost Price TargetOutperform$90.00 ➝ $120.00High
i
Rating by Matthew Biegler at Oppenheimer Holdings Inc.
9/21/2020HC WainwrightReiterated RatingBuy$88.00 ➝ $100.00High
i
Rating by Robert Burns at HC Wainwright
8/21/2020Canaccord GenuityBoost Price TargetPositive ➝ Buy$80.00 ➝ $85.00Low
i
8/19/2020Roth CapitalReiterated RatingPositive ➝ Buy$75.00 ➝ $77.00High
i
7/14/2020HC WainwrightReiterated RatingBuy$88.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/9/2020OppenheimerInitiated CoverageOutperform$90.00Low
i
6/23/2020HC WainwrightReiterated RatingBuy$88.00High
i
Rating by Robert Burns at HC Wainwright
5/26/2020HC WainwrightBoost Price TargetBuy$72.00 ➝ $88.00High
i
Rating by Robert Burns at HC Wainwright
5/14/2020Roth CapitalBoost Price TargetPositive ➝ Buy$65.00 ➝ $75.00High
i
Rating by Z. Jallah at Roth Capital
5/13/2020Wells Fargo & CompanyBoost Price TargetOverweight$62.00 ➝ $76.00High
i
5/13/2020SVB LeerinkBoost Price TargetOutperform$60.00 ➝ $67.00High
i
3/17/2020HC WainwrightBoost Price TargetBuy$70.00 ➝ $72.00High
i
Rating by Robert Burns at HC Wainwright
1/21/2020HC WainwrightReiterated RatingBuy$70.00Medium
i
Rating by Robert Burns at HC Wainwright
12/10/2019HC WainwrightReiterated RatingBuy$70.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
11/25/2019HC WainwrightReiterated RatingBuy$70.00High
i
Rating by R. Selvaraju at HC Wainwright
11/14/2019Roth CapitalInitiated CoverageBuy$65.00Medium
i
Rating by Z. Jallah at Roth Capital
11/12/2019HC WainwrightReiterated RatingBuy$70.00Medium
i
Rating by R. Selvaraju at HC Wainwright
9/25/2019HC WainwrightInitiated CoverageBuy$70.00Medium
i
Rating by R. Selvaraju at HC Wainwright
9/9/2019WedbushInitiated CoverageOutperform$63.00Low
i
Rating by D. Nierengarten at Wedbush
9/5/2019Canaccord GenuityBoost Price TargetBuy$53.00 ➝ $56.00High
i
9/4/2019Wells Fargo & CompanyBoost Price TargetOutperform$53.00 ➝ $62.00High
i
7/24/2019GuggenheimInitiated CoverageBuy ➝ Buy$58.00Medium
i
5/13/2019Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$48.00High
i
5/13/2019Canaccord GenuityInitiated CoverageBuy$48.00High
i
5/13/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$50.00High
i
5/13/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$53.00High
i
(Data available from 1/16/2016 forward)
Turning Point Therapeutics logo
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $131.60
$130.67
$139.65

50 Day Range

MA: $121.09
$103.46
$136.99

52 Week Range

Now: $131.60
$31.30
$139.81

Volume

206,961 shs

Average Volume

279,287 shs

Market Capitalization

$6.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Turning Point Therapeutics?

The following Wall Street sell-side analysts have issued reports on Turning Point Therapeutics in the last twelve months: Canaccord Genuity, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Roth Capital, SVB Leerink LLC, Wells Fargo & Company, and Zacks Investment Research.

What is the current price target for Turning Point Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Turning Point Therapeutics in the last year. Their average twelve-month price target is $137.43, suggesting a possible upside of 4.4%. JMP Securities has the highest price target set, predicting TPTX will reach $160.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $122.00 for Turning Point Therapeutics in the next year.

What is the current consensus analyst rating for Turning Point Therapeutics?

Turning Point Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TPTX will outperform the market and that investors should add to their positions of Turning Point Therapeutics.

What other companies compete with Turning Point Therapeutics?

Other companies that are similar to Turning Point Therapeutics include MERCK Kommanditgesellschaft auf Aktien, UCB, Royalty Pharma, Alnylam Pharmaceuticals, Catalent, CureVac, Horizon Therapeutics Public, BioMarin Pharmaceutical, Ono Pharmaceutical, Elanco Animal Health, Grifols, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, Mirati Therapeutics and Zai Lab.

How do I contact Turning Point Therapeutics' investor relations team?

Turning Point Therapeutics' physical mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company's listed phone number is 858-926-5251 and its investor relations email address is jim.mazzola@tptherapeutics.com. The official website for Turning Point Therapeutics is www.tptherapeutics.com.